| | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H13ClN3O |
| Molar mass | 310.76 g·mol−1 |
Trazium (EGYT-3,615) is an antidepressant drug which was never marketed. [1] It has psychostimulant-like effects and its actions appear to be mediated by the dopaminergic and adrenergic systems. [2] It was formulated as a salt with ethanesulfonic acid and given the generic name trazium esilate (INN).
Precursors: [3] [4] [5] Background literature: [6] [7] [8] [9]
Ex 5: The Grignard reaction between para-chlorophenylmagnesium bromide and 1-cyanoisoquinoline [1198-30-7] (1) gave 1-(4-chlorobenzoyl)isoquinoline, PC12243105 (2). The reaction of this with O-tosylhydroxylamine [52913-14-1] gives (2-aminoisoquinolin-2-ium-1-yl)-(4-chlorophenyl)methanone;4-methylbenzenesulfonate, PC23311140 (3). The reaction of this a mixture of formamide and phosphoryl chloride gave the ring. The addition of perchloric acid led to 1-(4-Chlorophenyl)[1,2,4]triazino[6,1-a]isoquinolin-5-ium perchlorate [82319-70-8] (4). The reaction of this with triethylammonium bromide is said to give (4).
Patent: [10]
Ex 1: 1-(4-chlorophenyl)-as-triazino[6,1-a]isoquinolinium-bromide [82319-85-5] (1) is reacted with an aqueous solution of acetonitrile to give the title compound. Ex 2: Treatment with ethanesulfonic acid in acetonitrile then prepares the esilate salt.